Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

Citigroup analyst Geoff Meacham has maintained a Buy rating on Kymera Therapeutics (NASDAQ: KYMR) and increased the price target from $135 to $150.